Complexity in influenza virus targeted drug design: interaction with human sialidases.

With the global spread of the pandemic H1N1 and the ongoing pandemic potential of the H5N1 subtype, the influenza virus represents one of the most alarming viruses spreading worldwide. The influenza virus sialidase is an effective drug target, and a number of inhibitors are clinically effective against the virus (zanamivir, oseltamivir, peramivir). Here we report structural and biochemical studies of the human cytosolic sialidase Neu2 with influenza virus sialidase-targeting drugs and related compounds.

[1]  G. Borsani,et al.  Properties of Recombinant Human Cytosolic Sialidase HsNEU2 , 2004, Journal of Biological Chemistry.

[2]  Frederick Hayden,et al.  Developing new antiviral agents for influenza treatment: what does the future hold? , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  W G Laver,et al.  Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. , 1997, Journal of the American Chemical Society.

[4]  Mark von Itzstein,et al.  The war against influenza: discovery and development of sialidase inhibitors. , 2007, Nature reviews. Drug discovery.

[5]  S. Maxwell,et al.  Tamiflu and neuropsychiatric disturbance in adolescents , 2007, BMJ : British Medical Journal.

[6]  D. M. Ryan,et al.  Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.

[7]  F. Hayden,et al.  Neuraminidase Sequence Analysis and Susceptibilities of Influenza Virus Clinical Isolates to Zanamivir and Oseltamivir , 2003, Antimicrobial Agents and Chemotherapy.

[8]  P. Colman,et al.  Structure and diversity of influenza virus neuraminidase. , 1985, Current topics in microbiology and immunology.

[9]  J. C. Dyason,et al.  Modelling, synthesis and biological evaluation of novel glucuronide-based probes of Vibrio cholerae sialidase. , 2006, Bioorganic & medicinal chemistry.

[10]  R. Compans,et al.  Effects of hexose starvation and the role of sialic acid in influenza virus release. , 1983, Virology.

[11]  Keiko Hata,et al.  Limited Inhibitory Effects of Oseltamivir and Zanamivir on Human Sialidases , 2008, Antimicrobial Agents and Chemotherapy.

[12]  Soichi Wakatsuki,et al.  Crystal Structure of the Human Cytosolic Sialidase Neu2 , 2005, Journal of Biological Chemistry.

[13]  K. Shen,et al.  Neuraminidase inhibitor, oseltamivir blocks GM1 ganglioside-regulated excitatory opioid receptor-mediated hyperalgesia, enhances opioid analgesia and attenuates tolerance in mice , 2004, Brain Research.

[14]  Brian J Smith,et al.  Structural studies of the resistance of influenza virus neuramindase to inhibitors. , 2002, Journal of medicinal chemistry.

[15]  M. Itzstein,et al.  An investigation of the activity of recombinant rat skeletal muscle cytosolic sialidase , 2005, FEBS letters.

[16]  Xiaowu Chen,et al.  Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. , 2000, Current medicinal chemistry.

[17]  R. Contreras,et al.  Dependence of neurotrophic factor activation of Trk tyrosine kinase receptors on cellular sialidase. , 2007, Glycobiology.

[18]  E. Cox,et al.  The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. , 2009, The New England journal of medicine.

[19]  K. Yamaguchi,et al.  Evidence for mitochondrial localization of a novel human sialidase (NEU4). , 2005, The Biochemical journal.

[20]  G. Borsani,et al.  Recent Development in Mammalian Sialidase Molecular Biology , 2002, Neurochemical Research.

[21]  P. Colman,et al.  Three‐dimensional structure of the complex of 4‐guanidino‐Neu5Ac2en and influenza virus neuraminidase , 1995, Protein science : a publication of the Protein Society.

[22]  A J Elliott,et al.  BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. , 2000, Journal of medicinal chemistry.

[23]  David J. Stevens,et al.  The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design , 2006, Nature.

[24]  Ying Sun,et al.  A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir , 2007, Cell Research.

[25]  S. Newman,et al.  Pharmacoscintigraphic Evaluation of Lung Deposition of Inhaled Zanamivir in Healthy Volunteers , 1999, Clinical pharmacokinetics.

[26]  A. Pshezhetsky,et al.  Lysosomal Sialidase (Neuraminidase-1) Is Targeted to the Cell Surface in a Multiprotein Complex That Facilitates Elastic Fiber Assembly* , 2006, Journal of Biological Chemistry.